Picture
SEARCH
What are you looking for?
Need help finding what you are looking for? Contact Us
Compare

PUBLISHER: 360iResearch | PRODUCT CODE: 1870858

Cover Image

PUBLISHER: 360iResearch | PRODUCT CODE: 1870858

Anorexia Nervosa Market by Treatment Type, Therapy Type, End User, Age Group - Global Forecast 2025-2032

PUBLISHED:
PAGES: 185 Pages
DELIVERY TIME: 1-2 business days
SELECT AN OPTION
PDF, Excel & 1 Year Online Access (Single User License)
USD 3939
PDF, Excel & 1 Year Online Access (2-5 User License)
USD 4249
PDF, Excel & 1 Year Online Access (Site License)
USD 5759
PDF, Excel & 1 Year Online Access (Enterprise User License)
USD 6969

Add to Cart

The Anorexia Nervosa Market is projected to grow by USD 298.60 million at a CAGR of 13.70% by 2032.

KEY MARKET STATISTICS
Base Year [2024] USD 106.87 million
Estimated Year [2025] USD 121.83 million
Forecast Year [2032] USD 298.60 million
CAGR (%) 13.70%

A comprehensive framing of anorexia nervosa that highlights integrated clinical imperatives, developmental tailoring, and the evolving delivery pathways for improved patient outcomes

Anorexia nervosa presents one of the most persistent and complex challenges in behavioral health, combining severe nutritional compromise with entrenched psychological patterns that demand coordinated clinical responses. Recent clinical practice and policy developments have heightened awareness of the condition's long-term morbidity and the need for integrated pathways across acute, intermediate, and community settings. Over the past decade clinicians and health systems have increasingly prioritized earlier identification, family-inclusive models of care, and multidisciplinary interventions that bridge medical stabilization, nutritional rehabilitation, and targeted psychotherapy.

This executive summary synthesizes clinically relevant evidence and service-delivery trends to support decision-makers in healthcare delivery, policy, and life sciences. It focuses on the modalities that shape care access and quality, including treatment settings, therapy approaches, provider types, and age-specific adaptations. While clinical nuance varies by patient presentation, common themes emerge: the imperative of tailoring interventions to developmental stage, the critical role of coordinated medical oversight during weight restoration, and the centrality of psychosocial therapies to sustain recovery. In addition, evolving care delivery mechanisms and payer interactions are influencing how services are organized and reimbursed, with implications for clinical outcomes and operational sustainability.

Taken together, these considerations underscore the need for strategic investments in workforce training, care integration, and evidence-based program design to meet rising clinical complexity and evolving patient expectations.

How technological adoption, earlier intervention strategies, and payer-driven integration are redefining care pathways and treatment intensity across clinical settings

The landscape of anorexia nervosa care has shifted markedly as clinical practice, technology, and policy intersect to reshape treatment trajectories and patient experience. Telehealth expansion has moved from a pandemic-era stopgap to a durable modality that augments in-person care, enabling continuity for patients across distances and improving access for those in underserved regions. Concurrently, digital assessment tools and remote monitoring platforms support clinicians in tracking physiological parameters and symptom trajectories between visits, which in turn informs more timely interventions and reduces risk during the critical early phases of treatment.

At the same time, clinical paradigms have evolved to favor earlier engagement and family-inclusive strategies, driven by evidence supporting improved outcomes with developmentally attuned interventions. Psychotherapeutic modalities such as cognitive behavioral therapy and family-based approaches have seen refinements in protocols and wider adoption across settings, while nutritional counseling has been integrated more closely with medical oversight to accelerate stabilization without compromising psychological work. Pharmacotherapy continues to play a secondary yet important role, primarily for co-occurring psychiatric symptoms and selective indications; the use of atypical antipsychotics and selective serotonin reuptake inhibitors remains targeted and adjunctive rather than primary.

These transformative shifts have been reinforced by payer and policy adjustments that emphasize stepped-care pathways, quality metrics tied to clinical outcomes, and incentives for integrated behavioral health models. As a result, providers and system leaders are redesigning care pathways to balance intensity, accessibility, and quality across day treatment programs, inpatient hospitalization, and residential treatment modalities.

Impacts of evolving tariff policies on supply chains, clinical trials logistics, and procurement strategies that influence continuity and cost of specialized anorexia nervosa care

Changes in tariff policy and cross-border trade dynamics have downstream effects on supply chains, pharmaceutical imports, and the cost structure of specialized medical equipment used in care delivery. For providers reliant on imported nutritional products, medical monitoring devices, or specialty formulations, shifts in tariffs alter procurement strategies and inventory management, prompting organizations to reassess sourcing arrangements and inventory buffers to maintain continuity of care. Health systems and independent providers are responding by broadening supplier panels, increasing local procurement where feasible, and negotiating more flexible contracting terms to mitigate exposure to tariff volatility.

Pharmaceutical development and clinical trials can also be affected indirectly through changes in the cost base for importing investigational supplies and equipment. Clinical program managers and sponsors are integrating tariff considerations into trial budgeting and logistics planning to avoid disruptions to dosing regimens or monitoring schedules. In tandem, international collaborations for research and training may require recalibration of resource flows and event planning when cross-border expenses shift.

Importantly, shifts in trade policy compel payer and provider procurement teams to adopt scenario planning that anticipates periods of price instability, with an emphasis on maintaining clinical quality and uninterrupted access to essential supplies. By embedding tariff sensitivity into supply-chain governance and contracting, organizations can preserve treatment continuity and protect vulnerable patients from gaps in care that could adversely affect clinical recovery trajectories.

Segmentation-driven insights that align treatment setting, therapeutic modality, provider type, and developmental stage to operationalize differentiated care pathways for better outcomes

Disaggregating the care continuum by treatment type reveals distinct resource and clinical intensity profiles that require differentiated operational responses. Day Treatment Program, Inpatient Hospitalization, and Residential Treatment each demand specific staffing models, clinical governance, and medical monitoring protocols; transitioning patients between these levels of care benefits from standardized handoffs and shared outcome metrics to minimize clinical regression. By contrast, therapy modality distinctions shape the clinical focus and training needs: Nutritional Counseling serves as the backbone of weight restoration and meal support, Pharmacotherapy-used selectively and inclusive of Atypical Antipsychotics and Selective Serotonin Reuptake Inhibitors-targets comorbid symptoms, and Psychotherapy-implemented through Cognitive Behavioral Therapy, Family Based Therapy, and Interpersonal Therapy-addresses the cognitive and relational drivers of illness.

End-user segmentation highlights where investment and innovation can have immediate operational impact. Hospitals deliver integrated medical stabilization and psychiatric liaison services; Specialized Clinics concentrate on multidisciplinary eating-disorder expertise and programmatic continuity; and Telehealth Providers extend reach and continuity through virtual platforms that support outpatient follow-up and caregiver coaching. Each end-user type faces unique challenges in workforce development, reimbursement navigation, and quality assurance.

Age-based considerations are equally critical: adolescents often require family-centered interventions and coordination with schools, adults may present with longer illness duration and comorbidities necessitating coordinated medical and psychiatric management, and children call for developmentally calibrated approaches that balance parental involvement with age-appropriate engagement. By weaving together treatment type, therapy approach, provider setting, and age group considerations, stakeholders can design care pathways that align clinical intensity with patient needs and system capacity.

A regional perspective on how clinical infrastructure, cultural dynamics, and policy frameworks shape access, service design, and innovation in eating-disorder care

Regional dynamics shape everything from clinical culture to regulatory frameworks and reimbursement practices, driving variation in service availability and care models across geographies. In the Americas, robust research infrastructure, concentrated centers of clinical excellence, and evolving payer models have driven innovations in integrated care pathways, while persistent access gaps remain in rural and underserved urban communities. Providers in this region increasingly adopt telehealth and collaborative care arrangements to extend specialty expertise into community settings, and payers are exploring value-based arrangements that reward sustained recovery and reduced medical complications.

Across Europe, Middle East & Africa, heterogeneity in healthcare systems produces a wide range of access and delivery models. Some European countries have well-established national pathways and funding mechanisms for specialized eating-disorder services, whereas other jurisdictions contend with limited specialist capacity and stigma-related barriers to care. In parts of the Middle East and Africa, community outreach and task-shared models are gaining traction to address shortages in specialist clinicians, and partnerships between public and private providers are emerging to expand access.

In the Asia-Pacific region, growing clinical recognition and investment in mental health services are expanding the landscape of care, yet cultural factors and resource constraints shape help-seeking behaviors and service design. Telehealth and digital education initiatives are accelerating uptake, while localized adaptations of evidence-based therapies aim to improve acceptability and adherence. Across all regions, cross-border collaboration in research, training, and guideline development offers opportunities to disseminate best practices and reduce fragmentation in service delivery.

Assessing the organizational landscape where integrated systems, specialized clinics, telehealth platforms, and clinical developers converge to deliver multidisciplinary care

The ecosystem of organizations active in anorexia nervosa care spans integrated health systems, specialized behavioral health clinics, telehealth platforms, and pharmaceutical and device developers that supply adjunctive tools for monitoring and symptom management. Health systems and hospitals serve as hubs for medical stabilization and complex comorbidity management, often partnering with specialized clinics to ensure continuity of psychosocial care. Specialized clinics concentrate expertise in multidisciplinary care teams, including dietitians, psychologists, psychiatrists, and nurse practitioners, and they often develop programmatic pathways that can be replicated across service lines.

Telehealth providers have scaled models for virtual therapy, caregiver coaching, and stepped-care follow-up, reducing geographic barriers to specialist consultation and enabling more frequent touchpoints that support adherence. Meanwhile, pharmaceutical companies and clinical-stage developers continue to explore pharmacologic approaches for symptom management and comorbidities, recognizing that medication remains adjunctive to core psychosocial and nutritional interventions. Device and digital health vendors are introducing remote monitoring tools and adherence supports that facilitate earlier clinical intervention and more granular outcome tracking.

From an operational perspective, collaboration across these organization types is critical: integrated pathways between hospitals, specialized clinics, and telehealth platforms reduce fragmentation; partnerships with technology vendors enhance monitoring capabilities; and strategic alignment with clinical researchers accelerates the translation of evidence into practice. Stakeholders that cultivate these collaborative linkages position themselves to deliver more coordinated, patient-centered care.

Actionable strategic priorities for healthcare executives to scale capacity, integrate telehealth, fortify procurement, and embed outcome-driven clinical governance

Leaders seeking to strengthen anorexia nervosa services should prioritize actions that scale clinical capacity while safeguarding quality and continuity. First, invest in workforce development that emphasizes competency-based training for multidisciplinary teams, including physicians, dietitians, mental health clinicians, and care coordinators, and embed standardized handoff protocols across levels of care to reduce risk during transitions. Second, integrate telehealth strategically to extend specialty reach and enable stepped-care models, combining high-intensity in-person programs with virtual follow-up and caregiver coaching to sustain gains and reduce readmissions.

Third, develop robust supply-chain and procurement strategies that anticipate cost volatility and ensure uninterrupted access to essential nutritional products and monitoring equipment. Fourth, strengthen measurement systems that track clinical outcomes, functional recovery, and patient experience, and use these metrics to inform continuous improvement and payer negotiations. Fifth, foster cross-sector partnerships with academic centers and clinical researchers to participate in trials and translational studies that expand treatment options and refine best practices.

Finally, prioritize equity and cultural competence in program design by adapting therapies and outreach approaches to meet the needs of diverse populations and reduce stigma-related barriers. By advancing these priorities in parallel-workforce, telehealth integration, procurement resilience, measurement, research partnerships, and equity-organizations can build sustainable programs that deliver measurable clinical benefit and improve long-term recovery trajectories.

A transparent multi-source methodology combining literature synthesis, expert interviews, and operational data to derive clinically grounded and implementable insights

This research synthesis combines systematic literature review, expert interviews, and cross-disciplinary evidence appraisal to ensure a comprehensive and clinically grounded perspective. Peer-reviewed clinical trials, practice guidelines, and consensus statements provided the clinical scaffold for therapy and treatment recommendations, while qualitative interviews with clinicians, program directors, and payers furnished operational context and insights into barriers to access and reimbursement dynamics. Data from service providers and technology vendors informed considerations of care delivery innovation, particularly the role of telehealth and remote monitoring.

Analytic rigor was maintained through triangulation of sources and iterative validation with subject-matter experts, including clinicians experienced in adolescent and adult eating-disorder care, dietitians, and clinical operations leaders. Where primary evidence was limited-such as in novel digital interventions or emerging procurement impacts-interpretation emphasized pragmatic implications rather than definitive claims, and uncertainty was explicitly noted. Ethical and methodological standards guided the inclusion of studies, with attention to study quality, sample characteristics, and generalizability to routine clinical settings.

The synthesis deliberately avoided speculative financial estimations and instead prioritized clinically meaningful patterns, operational levers, and regional considerations to support strategic decision-making by providers, payers, and commercial partners.

Synthesis of clinical and operational priorities that reinforce integrated, developmentally informed, and resilient approaches to delivering high-quality anorexia nervosa care

Anorexia nervosa care is at an inflection point where clinical advances, delivery-model innovation, and policy shifts create opportunities to improve outcomes but also demand strategic responses from organizations across the care continuum. The imperative is clear: prioritize early and family-inclusive interventions, integrate medical and psychosocial care, and leverage telehealth and digital monitoring to augment access and continuity. Concurrently, operational resilience-particularly in procurement and supply-chain planning-remains essential to prevent service interruptions that can undermine recovery.

Stakeholders that invest in workforce competencies, standardized care pathways, and cross-sector partnerships will be better positioned to translate evidence into routine practice and to meet diverse patient needs across developmental stages. Regional differences remain salient, and the most effective programs will adapt global best practices to local cultural, regulatory, and resource realities. Ultimately, progress will depend on aligning clinical excellence with sustainable operations and payer engagement so that high-quality, accessible care becomes the norm rather than the exception.

Product Code: MRR-1A1A064C0422

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Emergence of AI-enabled digital screening tools for early anorexia nervosa detection
  • 5.2. Expansion of telehealth platforms offering remote eating disorder therapy and support
  • 5.3. Integration of personalized nutritional supplements based on genetic and gut microbiome analysis
  • 5.4. Rising adoption of virtual reality exposure therapy to address body image distortions in patients
  • 5.5. Increased investment in mobile mental health apps with cognitive behavioral therapy modules for anorexia
  • 5.6. Growth of collaboration between insurance providers and specialist clinics to improve treatment access
  • 5.7. Development of peer-led online recovery communities leveraging social media for patient engagement

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Anorexia Nervosa Market, by Treatment Type

  • 8.1. Day Treatment Program
  • 8.2. Inpatient Hospitalization
  • 8.3. Residential Treatment

9. Anorexia Nervosa Market, by Therapy Type

  • 9.1. Nutritional Counseling
  • 9.2. Pharmacotherapy
    • 9.2.1. Atypical Antipsychotics
    • 9.2.2. Selective Serotonin Reuptake Inhibitors
  • 9.3. Psychotherapy
    • 9.3.1. Cognitive Behavioral Therapy
    • 9.3.2. Family Based Therapy
    • 9.3.3. Interpersonal Therapy

10. Anorexia Nervosa Market, by End User

  • 10.1. Hospitals
  • 10.2. Specialized Clinics
  • 10.3. Telehealth Providers

11. Anorexia Nervosa Market, by Age Group

  • 11.1. Adolescents
  • 11.2. Adults
  • 11.3. Children

12. Anorexia Nervosa Market, by Region

  • 12.1. Americas
    • 12.1.1. North America
    • 12.1.2. Latin America
  • 12.2. Europe, Middle East & Africa
    • 12.2.1. Europe
    • 12.2.2. Middle East
    • 12.2.3. Africa
  • 12.3. Asia-Pacific

13. Anorexia Nervosa Market, by Group

  • 13.1. ASEAN
  • 13.2. GCC
  • 13.3. European Union
  • 13.4. BRICS
  • 13.5. G7
  • 13.6. NATO

14. Anorexia Nervosa Market, by Country

  • 14.1. United States
  • 14.2. Canada
  • 14.3. Mexico
  • 14.4. Brazil
  • 14.5. United Kingdom
  • 14.6. Germany
  • 14.7. France
  • 14.8. Russia
  • 14.9. Italy
  • 14.10. Spain
  • 14.11. China
  • 14.12. India
  • 14.13. Japan
  • 14.14. Australia
  • 14.15. South Korea

15. Competitive Landscape

  • 15.1. Market Share Analysis, 2024
  • 15.2. FPNV Positioning Matrix, 2024
  • 15.3. Competitive Analysis
    • 15.3.1. Acadia Healthcare Company, Inc.
    • 15.3.2. Universal Health Services, Inc.
    • 15.3.3. Rogers Behavioral Health
    • 15.3.4. Eating Recovery Center, LLC
    • 15.3.5. Monte Nido & Affiliates, LLC
    • 15.3.6. Walden Behavioral Care, Inc.
    • 15.3.7. The Renfrew Center, Inc.
    • 15.3.8. Priory Group Ltd
Product Code: MRR-1A1A064C0422

LIST OF FIGURES

  • FIGURE 1. GLOBAL ANOREXIA NERVOSA MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL ANOREXIA NERVOSA MARKET SIZE, BY TREATMENT TYPE, 2024 VS 2032 (%)
  • FIGURE 3. GLOBAL ANOREXIA NERVOSA MARKET SIZE, BY TREATMENT TYPE, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 4. GLOBAL ANOREXIA NERVOSA MARKET SIZE, BY THERAPY TYPE, 2024 VS 2032 (%)
  • FIGURE 5. GLOBAL ANOREXIA NERVOSA MARKET SIZE, BY THERAPY TYPE, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL ANOREXIA NERVOSA MARKET SIZE, BY END USER, 2024 VS 2032 (%)
  • FIGURE 7. GLOBAL ANOREXIA NERVOSA MARKET SIZE, BY END USER, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL ANOREXIA NERVOSA MARKET SIZE, BY AGE GROUP, 2024 VS 2032 (%)
  • FIGURE 9. GLOBAL ANOREXIA NERVOSA MARKET SIZE, BY AGE GROUP, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL ANOREXIA NERVOSA MARKET SIZE, BY REGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 11. AMERICAS ANOREXIA NERVOSA MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 12. NORTH AMERICA ANOREXIA NERVOSA MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 13. LATIN AMERICA ANOREXIA NERVOSA MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 14. EUROPE, MIDDLE EAST & AFRICA ANOREXIA NERVOSA MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 15. EUROPE ANOREXIA NERVOSA MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 16. MIDDLE EAST ANOREXIA NERVOSA MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 17. AFRICA ANOREXIA NERVOSA MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 18. ASIA-PACIFIC ANOREXIA NERVOSA MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 19. GLOBAL ANOREXIA NERVOSA MARKET SIZE, BY GROUP, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 20. ASEAN ANOREXIA NERVOSA MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 21. GCC ANOREXIA NERVOSA MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 22. EUROPEAN UNION ANOREXIA NERVOSA MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 23. BRICS ANOREXIA NERVOSA MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 24. G7 ANOREXIA NERVOSA MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 25. NATO ANOREXIA NERVOSA MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 26. GLOBAL ANOREXIA NERVOSA MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 27. ANOREXIA NERVOSA MARKET SHARE, BY KEY PLAYER, 2024
  • FIGURE 28. ANOREXIA NERVOSA MARKET, FPNV POSITIONING MATRIX, 2024

LIST OF TABLES

  • TABLE 1. ANOREXIA NERVOSA MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
  • TABLE 3. GLOBAL ANOREXIA NERVOSA MARKET SIZE, 2018-2024 (USD MILLION)
  • TABLE 4. GLOBAL ANOREXIA NERVOSA MARKET SIZE, 2025-2032 (USD MILLION)
  • TABLE 5. GLOBAL ANOREXIA NERVOSA MARKET SIZE, BY TREATMENT TYPE, 2018-2024 (USD MILLION)
  • TABLE 6. GLOBAL ANOREXIA NERVOSA MARKET SIZE, BY TREATMENT TYPE, 2025-2032 (USD MILLION)
  • TABLE 7. GLOBAL ANOREXIA NERVOSA MARKET SIZE, BY DAY TREATMENT PROGRAM, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 8. GLOBAL ANOREXIA NERVOSA MARKET SIZE, BY DAY TREATMENT PROGRAM, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 9. GLOBAL ANOREXIA NERVOSA MARKET SIZE, BY DAY TREATMENT PROGRAM, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 10. GLOBAL ANOREXIA NERVOSA MARKET SIZE, BY DAY TREATMENT PROGRAM, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 11. GLOBAL ANOREXIA NERVOSA MARKET SIZE, BY DAY TREATMENT PROGRAM, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 12. GLOBAL ANOREXIA NERVOSA MARKET SIZE, BY DAY TREATMENT PROGRAM, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 13. GLOBAL ANOREXIA NERVOSA MARKET SIZE, BY INPATIENT HOSPITALIZATION, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 14. GLOBAL ANOREXIA NERVOSA MARKET SIZE, BY INPATIENT HOSPITALIZATION, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 15. GLOBAL ANOREXIA NERVOSA MARKET SIZE, BY INPATIENT HOSPITALIZATION, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 16. GLOBAL ANOREXIA NERVOSA MARKET SIZE, BY INPATIENT HOSPITALIZATION, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 17. GLOBAL ANOREXIA NERVOSA MARKET SIZE, BY INPATIENT HOSPITALIZATION, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 18. GLOBAL ANOREXIA NERVOSA MARKET SIZE, BY INPATIENT HOSPITALIZATION, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 19. GLOBAL ANOREXIA NERVOSA MARKET SIZE, BY RESIDENTIAL TREATMENT, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 20. GLOBAL ANOREXIA NERVOSA MARKET SIZE, BY RESIDENTIAL TREATMENT, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 21. GLOBAL ANOREXIA NERVOSA MARKET SIZE, BY RESIDENTIAL TREATMENT, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 22. GLOBAL ANOREXIA NERVOSA MARKET SIZE, BY RESIDENTIAL TREATMENT, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 23. GLOBAL ANOREXIA NERVOSA MARKET SIZE, BY RESIDENTIAL TREATMENT, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 24. GLOBAL ANOREXIA NERVOSA MARKET SIZE, BY RESIDENTIAL TREATMENT, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 25. GLOBAL ANOREXIA NERVOSA MARKET SIZE, BY THERAPY TYPE, 2018-2024 (USD MILLION)
  • TABLE 26. GLOBAL ANOREXIA NERVOSA MARKET SIZE, BY THERAPY TYPE, 2025-2032 (USD MILLION)
  • TABLE 27. GLOBAL ANOREXIA NERVOSA MARKET SIZE, BY NUTRITIONAL COUNSELING, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 28. GLOBAL ANOREXIA NERVOSA MARKET SIZE, BY NUTRITIONAL COUNSELING, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 29. GLOBAL ANOREXIA NERVOSA MARKET SIZE, BY NUTRITIONAL COUNSELING, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 30. GLOBAL ANOREXIA NERVOSA MARKET SIZE, BY NUTRITIONAL COUNSELING, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 31. GLOBAL ANOREXIA NERVOSA MARKET SIZE, BY NUTRITIONAL COUNSELING, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 32. GLOBAL ANOREXIA NERVOSA MARKET SIZE, BY NUTRITIONAL COUNSELING, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 33. GLOBAL ANOREXIA NERVOSA MARKET SIZE, BY PHARMACOTHERAPY, 2018-2024 (USD MILLION)
  • TABLE 34. GLOBAL ANOREXIA NERVOSA MARKET SIZE, BY PHARMACOTHERAPY, 2025-2032 (USD MILLION)
  • TABLE 35. GLOBAL ANOREXIA NERVOSA MARKET SIZE, BY PHARMACOTHERAPY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 36. GLOBAL ANOREXIA NERVOSA MARKET SIZE, BY PHARMACOTHERAPY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 37. GLOBAL ANOREXIA NERVOSA MARKET SIZE, BY PHARMACOTHERAPY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 38. GLOBAL ANOREXIA NERVOSA MARKET SIZE, BY PHARMACOTHERAPY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 39. GLOBAL ANOREXIA NERVOSA MARKET SIZE, BY PHARMACOTHERAPY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 40. GLOBAL ANOREXIA NERVOSA MARKET SIZE, BY PHARMACOTHERAPY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 41. GLOBAL ANOREXIA NERVOSA MARKET SIZE, BY ATYPICAL ANTIPSYCHOTICS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 42. GLOBAL ANOREXIA NERVOSA MARKET SIZE, BY ATYPICAL ANTIPSYCHOTICS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 43. GLOBAL ANOREXIA NERVOSA MARKET SIZE, BY ATYPICAL ANTIPSYCHOTICS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 44. GLOBAL ANOREXIA NERVOSA MARKET SIZE, BY ATYPICAL ANTIPSYCHOTICS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 45. GLOBAL ANOREXIA NERVOSA MARKET SIZE, BY ATYPICAL ANTIPSYCHOTICS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 46. GLOBAL ANOREXIA NERVOSA MARKET SIZE, BY ATYPICAL ANTIPSYCHOTICS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 47. GLOBAL ANOREXIA NERVOSA MARKET SIZE, BY SELECTIVE SEROTONIN REUPTAKE INHIBITORS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 48. GLOBAL ANOREXIA NERVOSA MARKET SIZE, BY SELECTIVE SEROTONIN REUPTAKE INHIBITORS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 49. GLOBAL ANOREXIA NERVOSA MARKET SIZE, BY SELECTIVE SEROTONIN REUPTAKE INHIBITORS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 50. GLOBAL ANOREXIA NERVOSA MARKET SIZE, BY SELECTIVE SEROTONIN REUPTAKE INHIBITORS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 51. GLOBAL ANOREXIA NERVOSA MARKET SIZE, BY SELECTIVE SEROTONIN REUPTAKE INHIBITORS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 52. GLOBAL ANOREXIA NERVOSA MARKET SIZE, BY SELECTIVE SEROTONIN REUPTAKE INHIBITORS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 53. GLOBAL ANOREXIA NERVOSA MARKET SIZE, BY PSYCHOTHERAPY, 2018-2024 (USD MILLION)
  • TABLE 54. GLOBAL ANOREXIA NERVOSA MARKET SIZE, BY PSYCHOTHERAPY, 2025-2032 (USD MILLION)
  • TABLE 55. GLOBAL ANOREXIA NERVOSA MARKET SIZE, BY PSYCHOTHERAPY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 56. GLOBAL ANOREXIA NERVOSA MARKET SIZE, BY PSYCHOTHERAPY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 57. GLOBAL ANOREXIA NERVOSA MARKET SIZE, BY PSYCHOTHERAPY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 58. GLOBAL ANOREXIA NERVOSA MARKET SIZE, BY PSYCHOTHERAPY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 59. GLOBAL ANOREXIA NERVOSA MARKET SIZE, BY PSYCHOTHERAPY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 60. GLOBAL ANOREXIA NERVOSA MARKET SIZE, BY PSYCHOTHERAPY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 61. GLOBAL ANOREXIA NERVOSA MARKET SIZE, BY COGNITIVE BEHAVIORAL THERAPY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 62. GLOBAL ANOREXIA NERVOSA MARKET SIZE, BY COGNITIVE BEHAVIORAL THERAPY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 63. GLOBAL ANOREXIA NERVOSA MARKET SIZE, BY COGNITIVE BEHAVIORAL THERAPY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 64. GLOBAL ANOREXIA NERVOSA MARKET SIZE, BY COGNITIVE BEHAVIORAL THERAPY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 65. GLOBAL ANOREXIA NERVOSA MARKET SIZE, BY COGNITIVE BEHAVIORAL THERAPY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 66. GLOBAL ANOREXIA NERVOSA MARKET SIZE, BY COGNITIVE BEHAVIORAL THERAPY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 67. GLOBAL ANOREXIA NERVOSA MARKET SIZE, BY FAMILY BASED THERAPY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 68. GLOBAL ANOREXIA NERVOSA MARKET SIZE, BY FAMILY BASED THERAPY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 69. GLOBAL ANOREXIA NERVOSA MARKET SIZE, BY FAMILY BASED THERAPY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 70. GLOBAL ANOREXIA NERVOSA MARKET SIZE, BY FAMILY BASED THERAPY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 71. GLOBAL ANOREXIA NERVOSA MARKET SIZE, BY FAMILY BASED THERAPY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 72. GLOBAL ANOREXIA NERVOSA MARKET SIZE, BY FAMILY BASED THERAPY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 73. GLOBAL ANOREXIA NERVOSA MARKET SIZE, BY INTERPERSONAL THERAPY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 74. GLOBAL ANOREXIA NERVOSA MARKET SIZE, BY INTERPERSONAL THERAPY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 75. GLOBAL ANOREXIA NERVOSA MARKET SIZE, BY INTERPERSONAL THERAPY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 76. GLOBAL ANOREXIA NERVOSA MARKET SIZE, BY INTERPERSONAL THERAPY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 77. GLOBAL ANOREXIA NERVOSA MARKET SIZE, BY INTERPERSONAL THERAPY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 78. GLOBAL ANOREXIA NERVOSA MARKET SIZE, BY INTERPERSONAL THERAPY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 79. GLOBAL ANOREXIA NERVOSA MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 80. GLOBAL ANOREXIA NERVOSA MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 81. GLOBAL ANOREXIA NERVOSA MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 82. GLOBAL ANOREXIA NERVOSA MARKET SIZE, BY HOSPITALS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 83. GLOBAL ANOREXIA NERVOSA MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 84. GLOBAL ANOREXIA NERVOSA MARKET SIZE, BY HOSPITALS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 85. GLOBAL ANOREXIA NERVOSA MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 86. GLOBAL ANOREXIA NERVOSA MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 87. GLOBAL ANOREXIA NERVOSA MARKET SIZE, BY SPECIALIZED CLINICS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 88. GLOBAL ANOREXIA NERVOSA MARKET SIZE, BY SPECIALIZED CLINICS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 89. GLOBAL ANOREXIA NERVOSA MARKET SIZE, BY SPECIALIZED CLINICS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 90. GLOBAL ANOREXIA NERVOSA MARKET SIZE, BY SPECIALIZED CLINICS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 91. GLOBAL ANOREXIA NERVOSA MARKET SIZE, BY SPECIALIZED CLINICS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 92. GLOBAL ANOREXIA NERVOSA MARKET SIZE, BY SPECIALIZED CLINICS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 93. GLOBAL ANOREXIA NERVOSA MARKET SIZE, BY TELEHEALTH PROVIDERS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 94. GLOBAL ANOREXIA NERVOSA MARKET SIZE, BY TELEHEALTH PROVIDERS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 95. GLOBAL ANOREXIA NERVOSA MARKET SIZE, BY TELEHEALTH PROVIDERS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 96. GLOBAL ANOREXIA NERVOSA MARKET SIZE, BY TELEHEALTH PROVIDERS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 97. GLOBAL ANOREXIA NERVOSA MARKET SIZE, BY TELEHEALTH PROVIDERS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 98. GLOBAL ANOREXIA NERVOSA MARKET SIZE, BY TELEHEALTH PROVIDERS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 99. GLOBAL ANOREXIA NERVOSA MARKET SIZE, BY AGE GROUP, 2018-2024 (USD MILLION)
  • TABLE 100. GLOBAL ANOREXIA NERVOSA MARKET SIZE, BY AGE GROUP, 2025-2032 (USD MILLION)
  • TABLE 101. GLOBAL ANOREXIA NERVOSA MARKET SIZE, BY ADOLESCENTS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 102. GLOBAL ANOREXIA NERVOSA MARKET SIZE, BY ADOLESCENTS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 103. GLOBAL ANOREXIA NERVOSA MARKET SIZE, BY ADOLESCENTS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 104. GLOBAL ANOREXIA NERVOSA MARKET SIZE, BY ADOLESCENTS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 105. GLOBAL ANOREXIA NERVOSA MARKET SIZE, BY ADOLESCENTS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 106. GLOBAL ANOREXIA NERVOSA MARKET SIZE, BY ADOLESCENTS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 107. GLOBAL ANOREXIA NERVOSA MARKET SIZE, BY ADULTS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 108. GLOBAL ANOREXIA NERVOSA MARKET SIZE, BY ADULTS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 109. GLOBAL ANOREXIA NERVOSA MARKET SIZE, BY ADULTS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 110. GLOBAL ANOREXIA NERVOSA MARKET SIZE, BY ADULTS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 111. GLOBAL ANOREXIA NERVOSA MARKET SIZE, BY ADULTS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 112. GLOBAL ANOREXIA NERVOSA MARKET SIZE, BY ADULTS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 113. GLOBAL ANOREXIA NERVOSA MARKET SIZE, BY CHILDREN, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 114. GLOBAL ANOREXIA NERVOSA MARKET SIZE, BY CHILDREN, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 115. GLOBAL ANOREXIA NERVOSA MARKET SIZE, BY CHILDREN, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 116. GLOBAL ANOREXIA NERVOSA MARKET SIZE, BY CHILDREN, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 117. GLOBAL ANOREXIA NERVOSA MARKET SIZE, BY CHILDREN, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 118. GLOBAL ANOREXIA NERVOSA MARKET SIZE, BY CHILDREN, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 119. GLOBAL ANOREXIA NERVOSA MARKET SIZE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 120. GLOBAL ANOREXIA NERVOSA MARKET SIZE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 121. AMERICAS ANOREXIA NERVOSA MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
  • TABLE 122. AMERICAS ANOREXIA NERVOSA MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
  • TABLE 123. AMERICAS ANOREXIA NERVOSA MARKET SIZE, BY TREATMENT TYPE, 2018-2024 (USD MILLION)
  • TABLE 124. AMERICAS ANOREXIA NERVOSA MARKET SIZE, BY TREATMENT TYPE, 2025-2032 (USD MILLION)
  • TABLE 125. AMERICAS ANOREXIA NERVOSA MARKET SIZE, BY THERAPY TYPE, 2018-2024 (USD MILLION)
  • TABLE 126. AMERICAS ANOREXIA NERVOSA MARKET SIZE, BY THERAPY TYPE, 2025-2032 (USD MILLION)
  • TABLE 127. AMERICAS ANOREXIA NERVOSA MARKET SIZE, BY PHARMACOTHERAPY, 2018-2024 (USD MILLION)
  • TABLE 128. AMERICAS ANOREXIA NERVOSA MARKET SIZE, BY PHARMACOTHERAPY, 2025-2032 (USD MILLION)
  • TABLE 129. AMERICAS ANOREXIA NERVOSA MARKET SIZE, BY PSYCHOTHERAPY, 2018-2024 (USD MILLION)
  • TABLE 130. AMERICAS ANOREXIA NERVOSA MARKET SIZE, BY PSYCHOTHERAPY, 2025-2032 (USD MILLION)
  • TABLE 131. AMERICAS ANOREXIA NERVOSA MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 132. AMERICAS ANOREXIA NERVOSA MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 133. AMERICAS ANOREXIA NERVOSA MARKET SIZE, BY AGE GROUP, 2018-2024 (USD MILLION)
  • TABLE 134. AMERICAS ANOREXIA NERVOSA MARKET SIZE, BY AGE GROUP, 2025-2032 (USD MILLION)
  • TABLE 135. NORTH AMERICA ANOREXIA NERVOSA MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 136. NORTH AMERICA ANOREXIA NERVOSA MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 137. NORTH AMERICA ANOREXIA NERVOSA MARKET SIZE, BY TREATMENT TYPE, 2018-2024 (USD MILLION)
  • TABLE 138. NORTH AMERICA ANOREXIA NERVOSA MARKET SIZE, BY TREATMENT TYPE, 2025-2032 (USD MILLION)
  • TABLE 139. NORTH AMERICA ANOREXIA NERVOSA MARKET SIZE, BY THERAPY TYPE, 2018-2024 (USD MILLION)
  • TABLE 140. NORTH AMERICA ANOREXIA NERVOSA MARKET SIZE, BY THERAPY TYPE, 2025-2032 (USD MILLION)
  • TABLE 141. NORTH AMERICA ANOREXIA NERVOSA MARKET SIZE, BY PHARMACOTHERAPY, 2018-2024 (USD MILLION)
  • TABLE 142. NORTH AMERICA ANOREXIA NERVOSA MARKET SIZE, BY PHARMACOTHERAPY, 2025-2032 (USD MILLION)
  • TABLE 143. NORTH AMERICA ANOREXIA NERVOSA MARKET SIZE, BY PSYCHOTHERAPY, 2018-2024 (USD MILLION)
  • TABLE 144. NORTH AMERICA ANOREXIA NERVOSA MARKET SIZE, BY PSYCHOTHERAPY, 2025-2032 (USD MILLION)
  • TABLE 145. NORTH AMERICA ANOREXIA NERVOSA MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 146. NORTH AMERICA ANOREXIA NERVOSA MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 147. NORTH AMERICA ANOREXIA NERVOSA MARKET SIZE, BY AGE GROUP, 2018-2024 (USD MILLION)
  • TABLE 148. NORTH AMERICA ANOREXIA NERVOSA MARKET SIZE, BY AGE GROUP, 2025-2032 (USD MILLION)
  • TABLE 149. LATIN AMERICA ANOREXIA NERVOSA MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 150. LATIN AMERICA ANOREXIA NERVOSA MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 151. LATIN AMERICA ANOREXIA NERVOSA MARKET SIZE, BY TREATMENT TYPE, 2018-2024 (USD MILLION)
  • TABLE 152. LATIN AMERICA ANOREXIA NERVOSA MARKET SIZE, BY TREATMENT TYPE, 2025-2032 (USD MILLION)
  • TABLE 153. LATIN AMERICA ANOREXIA NERVOSA MARKET SIZE, BY THERAPY TYPE, 2018-2024 (USD MILLION)
  • TABLE 154. LATIN AMERICA ANOREXIA NERVOSA MARKET SIZE, BY THERAPY TYPE, 2025-2032 (USD MILLION)
  • TABLE 155. LATIN AMERICA ANOREXIA NERVOSA MARKET SIZE, BY PHARMACOTHERAPY, 2018-2024 (USD MILLION)
  • TABLE 156. LATIN AMERICA ANOREXIA NERVOSA MARKET SIZE, BY PHARMACOTHERAPY, 2025-2032 (USD MILLION)
  • TABLE 157. LATIN AMERICA ANOREXIA NERVOSA MARKET SIZE, BY PSYCHOTHERAPY, 2018-2024 (USD MILLION)
  • TABLE 158. LATIN AMERICA ANOREXIA NERVOSA MARKET SIZE, BY PSYCHOTHERAPY, 2025-2032 (USD MILLION)
  • TABLE 159. LATIN AMERICA ANOREXIA NERVOSA MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 160. LATIN AMERICA ANOREXIA NERVOSA MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 161. LATIN AMERICA ANOREXIA NERVOSA MARKET SIZE, BY AGE GROUP, 2018-2024 (USD MILLION)
  • TABLE 162. LATIN AMERICA ANOREXIA NERVOSA MARKET SIZE, BY AGE GROUP, 2025-2032 (USD MILLION)
  • TABLE 163. EUROPE, MIDDLE EAST & AFRICA ANOREXIA NERVOSA MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
  • TABLE 164. EUROPE, MIDDLE EAST & AFRICA ANOREXIA NERVOSA MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
  • TABLE 165. EUROPE, MIDDLE EAST & AFRICA ANOREXIA NERVOSA MARKET SIZE, BY TREATMENT TYPE, 2018-2024 (USD MILLION)
  • TABLE 166. EUROPE, MIDDLE EAST & AFRICA ANOREXIA NERVOSA MARKET SIZE, BY TREATMENT TYPE, 2025-2032 (USD MILLION)
  • TABLE 167. EUROPE, MIDDLE EAST & AFRICA ANOREXIA NERVOSA MARKET SIZE, BY THERAPY TYPE, 2018-2024 (USD MILLION)
  • TABLE 168. EUROPE, MIDDLE EAST & AFRICA ANOREXIA NERVOSA MARKET SIZE, BY THERAPY TYPE, 2025-2032 (USD MILLION)
  • TABLE 169. EUROPE, MIDDLE EAST & AFRICA ANOREXIA NERVOSA MARKET SIZE, BY PHARMACOTHERAPY, 2018-2024 (USD MILLION)
  • TABLE 170. EUROPE, MIDDLE EAST & AFRICA ANOREXIA NERVOSA MARKET SIZE, BY PHARMACOTHERAPY, 2025-2032 (USD MILLION)
  • TABLE 171. EUROPE, MIDDLE EAST & AFRICA ANOREXIA NERVOSA MARKET SIZE, BY PSYCHOTHERAPY, 2018-2024 (USD MILLION)
  • TABLE 172. EUROPE, MIDDLE EAST & AFRICA ANOREXIA NERVOSA MARKET SIZE, BY PSYCHOTHERAPY, 2025-2032 (USD MILLION)
  • TABLE 173. EUROPE, MIDDLE EAST & AFRICA ANOREXIA NERVOSA MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 174. EUROPE, MIDDLE EAST & AFRICA ANOREXIA NERVOSA MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 175. EUROPE, MIDDLE EAST & AFRICA ANOREXIA NERVOSA MARKET SIZE, BY AGE GROUP, 2018-2024 (USD MILLION)
  • TABLE 176. EUROPE, MIDDLE EAST & AFRICA ANOREXIA NERVOSA MARKET SIZE, BY AGE GROUP, 2025-2032 (USD MILLION)
  • TABLE 177. EUROPE ANOREXIA NERVOSA MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 178. EUROPE ANOREXIA NERVOSA MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 179. EUROPE ANOREXIA NERVOSA MARKET SIZE, BY TREATMENT TYPE, 2018-2024 (USD MILLION)
  • TABLE 180. EUROPE ANOREXIA NERVOSA MARKET SIZE, BY TREATMENT TYPE, 2025-2032 (USD MILLION)
  • TABLE 181. EUROPE ANOREXIA NERVOSA MARKET SIZE, BY THERAPY TYPE, 2018-2024 (USD MILLION)
  • TABLE 182. EUROPE ANOREXIA NERVOSA MARKET SIZE, BY THERAPY TYPE, 2025-2032 (USD MILLION)
  • TABLE 183. EUROPE ANOREXIA NERVOSA MARKET SIZE, BY PHARMACOTHERAPY, 2018-2024 (USD MILLION)
  • TABLE 184. EUROPE ANOREXIA NERVOSA MARKET SIZE, BY PHARMACOTHERAPY, 2025-2032 (USD MILLION)
  • TABLE 185. EUROPE ANOREXIA NERVOSA MARKET SIZE, BY PSYCHOTHERAPY, 2018-2024 (USD MILLION)
  • TABLE 186. EUROPE ANOREXIA NERVOSA MARKET SIZE, BY PSYCHOTHERAPY, 2025-2032 (USD MILLION)
  • TABLE 187. EUROPE ANOREXIA NERVOSA MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 188. EUROPE ANOREXIA NERVOSA MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 189. EUROPE ANOREXIA NERVOSA MARKET SIZE, BY AGE GROUP, 2018-2024 (USD MILLION)
  • TABLE 190. EUROPE ANOREXIA NERVOSA MARKET SIZE, BY AGE GROUP, 2025-2032 (USD MILLION)
  • TABLE 191. MIDDLE EAST ANOREXIA NERVOSA MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 192. MIDDLE EAST ANOREXIA NERVOSA MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 193. MIDDLE EAST ANOREXIA NERVOSA MARKET SIZE, BY TREATMENT TYPE, 2018-2024 (USD MILLION)
  • TABLE 194. MIDDLE EAST ANOREXIA NERVOSA MARKET SIZE, BY TREATMENT TYPE, 2025-2032 (USD MILLION)
  • TABLE 195. MIDDLE EAST ANOREXIA NERVOSA MARKET SIZE, BY THERAPY TYPE, 2018-2024 (USD MILLION)
  • TABLE 196. MIDDLE EAST ANOREXIA NERVOSA MARKET SIZE, BY THERAPY TYPE, 2025-2032 (USD MILLION)
  • TABLE 197. MIDDLE EAST ANOREXIA NERVOSA MARKET SIZE, BY PHARMACOTHERAPY, 2018-2024 (USD MILLION)
  • TABLE 198. MIDDLE EAST ANOREXIA NERVOSA MARKET SIZE, BY PHARMACOTHERAPY, 2025-2032 (USD MILLION)
  • TABLE 199. MIDDLE EAST ANOREXIA NERVOSA MARKET SIZE, BY PSYCHOTHERAPY, 2018-2024 (USD MILLION)
  • TABLE 200. MIDDLE EAST ANOREXIA NERVOSA MARKET SIZE, BY PSYCHOTHERAPY, 2025-2032 (USD MILLION)
  • TABLE 201. MIDDLE EAST ANOREXIA NERVOSA MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 202. MIDDLE EAST ANOREXIA NERVOSA MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 203. MIDDLE EAST ANOREXIA NERVOSA MARKET SIZE, BY AGE GROUP, 2018-2024 (USD MILLION)
  • TABLE 204. MIDDLE EAST ANOREXIA NERVOSA MARKET SIZE, BY AGE GROUP, 2025-2032 (USD MILLION)
  • TABLE 205. AFRICA ANOREXIA NERVOSA MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 206. AFRICA ANOREXIA NERVOSA MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 207. AFRICA ANOREXIA NERVOSA MARKET SIZE, BY TREATMENT TYPE, 2018-2024 (USD MILLION)
  • TABLE 208. AFRICA ANOREXIA NERVOSA MARKET SIZE, BY TREATMENT TYPE, 2025-2032 (USD MILLION)
  • TABLE 209. AFRICA ANOREXIA NERVOSA MARKET SIZE, BY THERAPY TYPE, 2018-2024 (USD MILLION)
  • TABLE 210. AFRICA ANOREXIA NERVOSA MARKET SIZE, BY THERAPY TYPE, 2025-2032 (USD MILLION)
  • TABLE 211. AFRICA ANOREXIA NERVOSA MARKET SIZE, BY PHARMACOTHERAPY, 2018-2024 (USD MILLION)
  • TABLE 212. AFRICA ANOREXIA NERVOSA MARKET SIZE, BY PHARMACOTHERAPY, 2025-2032 (USD MILLION)
  • TABLE 213. AFRICA ANOREXIA NERVOSA MARKET SIZE, BY PSYCHOTHERAPY, 2018-2024 (USD MILLION)
  • TABLE 214. AFRICA ANOREXIA NERVOSA MARKET SIZE, BY PSYCHOTHERAPY, 2025-2032 (USD MILLION)
  • TABLE 215. AFRICA ANOREXIA NERVOSA MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 216. AFRICA ANOREXIA NERVOSA MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 217. AFRICA ANOREXIA NERVOSA MARKET SIZE, BY AGE GROUP, 2018-2024 (USD MILLION)
  • TABLE 218. AFRICA ANOREXIA NERVOSA MARKET SIZE, BY AGE GROUP, 2025-2032 (USD MILLION)
  • TABLE 219. ASIA-PACIFIC ANOREXIA NERVOSA MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 220. ASIA-PACIFIC ANOREXIA NERVOSA MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 221. ASIA-PACIFIC ANOREXIA NERVOSA MARKET SIZE, BY TREATMENT TYPE, 2018-2024 (USD MILLION)
  • TABLE 222. ASIA-PACIFIC ANOREXIA NERVOSA MARKET SIZE, BY TREATMENT TYPE, 2025-2032 (USD MILLION)
  • TABLE 223. ASIA-PACIFIC ANOREXIA NERVOSA MARKET SIZE, BY THERAPY TYPE, 2018-2024 (USD MILLION)
  • TABLE 224. ASIA-PACIFIC ANOREXIA NERVOSA MARKET SIZE, BY THERAPY TYPE, 2025-2032 (USD MILLION)
  • TABLE 225. ASIA-PACIFIC ANOREXIA NERVOSA MARKET SIZE, BY PHARMACOTHERAPY, 2018-2024 (USD MILLION)
  • TABLE 226. ASIA-PACIFIC ANOREXIA NERVOSA MARKET SIZE, BY PHARMACOTHERAPY, 2025-2032 (USD MILLION)
  • TABLE 227. ASIA-PACIFIC ANOREXIA NERVOSA MARKET SIZE, BY PSYCHOTHERAPY, 2018-2024 (USD MILLION)
  • TABLE 228. ASIA-PACIFIC ANOREXIA NERVOSA MARKET SIZE, BY PSYCHOTHERAPY, 2025-2032 (USD MILLION)
  • TABLE 229. ASIA-PACIFIC ANOREXIA NERVOSA MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 230. ASIA-PACIFIC ANOREXIA NERVOSA MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 231. ASIA-PACIFIC ANOREXIA NERVOSA MARKET SIZE, BY AGE GROUP, 2018-2024 (USD MILLION)
  • TABLE 232. ASIA-PACIFIC ANOREXIA NERVOSA MARKET SIZE, BY AGE GROUP, 2025-2032 (USD MILLION)
  • TABLE 233. GLOBAL ANOREXIA NERVOSA MARKET SIZE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 234. GLOBAL ANOREXIA NERVOSA MARKET SIZE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 235. ASEAN ANOREXIA NERVOSA MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 236. ASEAN ANOREXIA NERVOSA MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 237. ASEAN ANOREXIA NERVOSA MARKET SIZE, BY TREATMENT TYPE, 2018-2024 (USD MILLION)
  • TABLE 238. ASEAN ANOREXIA NERVOSA MARKET SIZE, BY TREATMENT TYPE, 2025-2032 (USD MILLION)
  • TABLE 239. ASEAN ANOREXIA NERVOSA MARKET SIZE, BY THERAPY TYPE, 2018-2024 (USD MILLION)
  • TABLE 240. ASEAN ANOREXIA NERVOSA MARKET SIZE, BY THERAPY TYPE, 2025-2032 (USD MILLION)
  • TABLE 241. ASEAN ANOREXIA NERVOSA MARKET SIZE, BY PHARMACOTHERAPY, 2018-2024 (USD MILLION)
  • TABLE 242. ASEAN ANOREXIA NERVOSA MARKET SIZE, BY PHARMACOTHERAPY, 2025-2032 (USD MILLION)
  • TABLE 243. ASEAN ANOREXIA NERVOSA MARKET SIZE, BY PSYCHOTHERAPY, 2018-2024 (USD MILLION)
  • TABLE 244. ASEAN ANOREXIA NERVOSA MARKET SIZE, BY PSYCHOTHERAPY, 2025-2032 (USD MILLION)
  • TABLE 245. ASEAN ANOREXIA NERVOSA MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 246. ASEAN ANOREXIA NERVOSA MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 247. ASEAN ANOREXIA NERVOSA MARKET SIZE, BY AGE GROUP, 2018-2024 (USD MILLION)
  • TABLE 248. ASEAN ANOREXIA NERVOSA MARKET SIZE, BY AGE GROUP, 2025-2032 (USD MILLION)
  • TABLE 249. GCC ANOREXIA NERVOSA MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 250. GCC ANOREXIA NERVOSA MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 251. GCC ANOREXIA NERVOSA MARKET SIZE, BY TREATMENT TYPE, 2018-2024 (USD MILLION)
  • TABLE 252. GCC ANOREXIA NERVOSA MARKET SIZE, BY TREATMENT TYPE, 2025-2032 (USD MILLION)
  • TABLE 253. GCC ANOREXIA NERVOSA MARKET SIZE, BY THERAPY TYPE, 2018-2024 (USD MILLION)
  • TABLE 254. GCC ANOREXIA NERVOSA MARKET SIZE, BY THERAPY TYPE, 2025-2032 (USD MILLION)
  • TABLE 255. GCC ANOREXIA NERVOSA MARKET SIZE, BY PHARMACOTHERAPY, 2018-2024 (USD MILLION)
  • TABLE 256. GCC ANOREXIA NERVOSA MARKET SIZE, BY PHARMACOTHERAPY, 2025-2032 (USD MILLION)
  • TABLE 257. GCC ANOREXIA NERVOSA MARKET SIZE, BY PSYCHOTHERAPY, 2018-2024 (USD MILLION)
  • TABLE 258. GCC ANOREXIA NERVOSA MARKET SIZE, BY PSYCHOTHERAPY, 2025-2032 (USD MILLION)
  • TABLE 259. GCC ANOREXIA NERVOSA MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 260. GCC ANOREXIA NERVOSA MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 261. GCC ANOREXIA NERVOSA MARKET SIZE, BY AGE GROUP, 2018-2024 (USD MILLION)
  • TABLE 262. GCC ANOREXIA NERVOSA MARKET SIZE, BY AGE GROUP, 2025-2032 (USD MILLION)
  • TABLE 263. EUROPEAN UNION ANOREXIA NERVOSA MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 264. EUROPEAN UNION ANOREXIA NERVOSA MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 265. EUROPEAN UNION ANOREXIA NERVOSA MARKET SIZE, BY TREATMENT TYPE, 2018-2024 (USD MILLION)
  • TABLE 266. EUROPEAN UNION ANOREXIA NERVOSA MARKET SIZE, BY TREATMENT TYPE, 2025-2032 (USD MILLION)
  • TABLE 267. EUROPEAN UNION ANOREXIA NERVOSA MARKET SIZE, BY THERAPY TYPE, 2018-2024 (USD MILLION)
  • TABLE 268. EUROPEAN UNION ANOREXIA NERVOSA MARKET SIZE, BY THERAPY TYPE, 2025-2032 (USD MILLION)
  • TABLE 269. EUROPEAN UNION ANOREXIA NERVOSA MARKET SIZE, BY PHARMACOTHERAPY, 2018-2024 (USD MILLION)
  • TABLE 270. EUROPEAN UNION ANOREXIA NERVOSA MARKET SIZE, BY PHARMACOTHERAPY, 2025-2032 (USD MILLION)
  • TABLE 271. EUROPEAN UNION ANOREXIA NERVOSA MARKET SIZE, BY PSYCHOTHERAPY, 2018-2024 (USD MILLION)
  • TABLE 272. EUROPEAN UNION ANOREXIA NERVOSA MARKET SIZE, BY PSYCHOTHERAPY, 2025-2032 (USD MILLION)
  • TABLE 273. EUROPEAN UNION ANOREXIA NERVOSA MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 274. EUROPEAN UNION ANOREXIA NERVOSA MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 275. EUROPEAN UNION ANOREXIA NERVOSA MARKET SIZE, BY AGE GROUP, 2018-2024 (USD MILLION)
  • TABLE 276. EUROPEAN UNION ANOREXIA NERVOSA MARKET SIZE, BY AGE GROUP, 2025-2032 (USD MILLION)
  • TABLE 277. BRICS ANOREXIA NERVOSA MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 278. BRICS ANOREXIA NERVOSA MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 279. BRICS ANOREXIA NERVOSA MARKET SIZE, BY TREATMENT TYPE, 2018-2024 (USD MILLION)
  • TABLE 280. BRICS ANOREXIA NERVOSA MARKET SIZE, BY TREATMENT TYPE, 2025-2032 (USD MILLION)
  • TABLE 281. BRICS ANOREXIA NERVOSA MARKET SIZE, BY THERAPY TYPE, 2018-2024 (USD MILLION)
  • TABLE 282. BRICS ANOREXIA NERVOSA MARKET SIZE, BY THERAPY TYPE, 2025-2032 (USD MILLION)
  • TABLE 283. BRICS ANOREXIA NERVOSA MARKET SIZE, BY PHARMACOTHERAPY, 2018-2024 (USD MILLION)
  • TABLE 284. BRICS ANOREXIA NERVOSA MARKET SIZE, BY PHARMACOTHERAPY, 2025-2032 (USD MILLION)
  • TABLE 285. BRICS ANOREXIA NERVOSA MARKET SIZE, BY PSYCHOTHERAPY, 2018-2024 (USD MILLION)
  • TABLE 286. BRICS ANOREXIA NERVOSA MARKET SIZE, BY PSYCHOTHERAPY, 2025-2032 (USD MILLION)
  • TABLE 287. BRICS ANOREXIA NERVOSA MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 288. BRICS ANOREXIA NERVOSA MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 289. BRICS ANOREXIA NERVOSA MARKET SIZE, BY AGE GROUP, 2018-2024 (USD MILLION)
  • TABLE 290. BRICS ANOREXIA NERVOSA MARKET SIZE, BY AGE GROUP, 2025-2032 (USD MILLION)
  • TABLE 291. G7 ANOREXIA NERVOSA MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 292. G7 ANOREXIA NERVOSA MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 293. G7 ANOREXIA NERVOSA MARKET SIZE, BY TREATMENT TYPE, 2018-2024 (USD MILLION)
  • TABLE 294. G7 ANOREXIA NERVOSA MARKET SIZE, BY TREATMENT TYPE, 2025-2032 (USD MILLION)
  • TABLE 295. G7 ANOREXIA NERVOSA MARKET SIZE, BY THERAPY TYPE, 2018-2024 (USD MILLION)
  • TABLE 296. G7 ANOREXIA NERVOSA MARKET SIZE, BY THERAPY TYPE, 2025-2032 (USD MILLION)
  • TABLE 297. G7 ANOREXIA NERVOSA MARKET SIZE, BY PHARMACOTHERAPY, 2018-2024 (USD MILLION)
  • TABLE 298. G7 ANOREXIA NERVOSA MARKET SIZE, BY PHARMACOTHERAPY, 2025-2032 (USD MILLION)
  • TABLE 299. G7 ANOREXIA NERVOSA MARKET SIZE, BY PSYCHOTHERAPY, 2018-2024 (USD MILLION)
  • TABLE 300. G7 ANOREXIA NERVOSA MARKET SIZE, BY PSYCHOTHERAPY, 2025-2032 (USD MILLION)
  • TABLE 301. G7 ANOREXIA NERVOSA MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 302. G7 ANOREXIA NERVOSA MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 303. G7 ANOREXIA NERVOSA MARKET SIZE, BY AGE GROUP, 2018-2024 (USD MILLION)
  • TABLE 304. G7 ANOREXIA NERVOSA MARKET SIZE, BY AGE GROUP, 2025-2032 (USD MILLION)
  • TABLE 305. NATO ANOREXIA NERVOSA MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 306. NATO ANOREXIA NERVOSA MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 307. NATO ANOREXIA NERVOSA MARKET SIZE, BY TREATMENT TYPE, 2018-2024 (USD MILLION)
  • TABLE 308. NATO ANOREXIA NERVOSA MARKET SIZE, BY TREATMENT TYPE, 2025-2032 (USD MILLION)
  • TABLE 309. NATO ANOREXIA NERVOSA MARKET SIZE, BY THERAPY TYPE, 2018-2024 (USD MILLION)
  • TABLE 310. NATO ANOREXIA NERVOSA MARKET SIZE, BY THERAPY TYPE, 2025-2032 (USD MILLION)
  • TABLE 311. NATO ANOREXIA NERVOSA MARKET SIZE, BY PHARMACOTHERAPY, 2018-2024 (USD MILLION)
  • TABLE 312. NATO ANOREXIA NERVOSA MARKET SIZE, BY PHARMACOTHERAPY, 2025-2032 (USD MILLION)
  • TABLE 313. NATO ANOREXIA NERVOSA MARKET SIZE, BY PSYCHOTHERAPY, 2018-2024 (USD MILLION)
  • TABLE 314. NATO ANOREXIA NERVOSA MARKET SIZE, BY PSYCHOTHERAPY, 2025-2032 (USD MILLION)
  • TABLE 315. NATO ANOREXIA NERVOSA MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 316. NATO ANOREXIA NERVOSA MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 317. NATO ANOREXIA NERVOSA MARKET SIZE, BY AGE GROUP, 2018-2024 (USD MILLION)
  • TABLE 318. NATO ANOREXIA NERVOSA MARKET SIZE, BY AGE GROUP, 2025-2032 (USD MILLION)
  • TABLE 319. GLOBAL ANOREXIA NERVOSA MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 320. GLOBAL ANOREXIA NERVOSA MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 321. UNITED STATES ANOREXIA NERVOSA MARKET SIZE, BY TREATMENT TYPE, 2018-2024 (USD MILLION)
  • TABLE 322. UNITED STATES ANOREXIA NERVOSA MARKET SIZE, BY TREATMENT TYPE, 2025-2032 (USD MILLION)
  • TABLE 323. UNITED STATES ANOREXIA NERVOSA MARKET SIZE, BY THERAPY TYPE, 2018-2024 (USD MILLION)
  • TABLE 324. UNITED STATES ANOREXIA NERVOSA MARKET SIZE, BY THERAPY TYPE, 2025-2032 (USD MILLION)
  • TABLE 325. UNITED STATES ANOREXIA NERVOSA MARKET SIZE, BY PHARMACOTHERAPY, 2018-2024 (USD MILLION)
  • TABLE 326. UNITED STATES ANOREXIA NERVOSA MARKET SIZE, BY PHARMACOTHERAPY, 2025-2032 (USD MILLION)
  • TABLE 327. UNITED STATES ANOREXIA NERVOSA MARKET SIZE, BY PSYCHOTHERAPY, 2018-2024 (USD MILLION)
  • TABLE 328. UNITED STATES ANOREXIA NERVOSA MARKET SIZE, BY PSYCHOTHERAPY, 2025-2032 (USD MILLION)
  • TABLE 329. UNITED STATES ANOREXIA NERVOSA MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 330. UNITED STATES ANOREXIA NERVOSA MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 331. UNITED STATES ANOREXIA NERVOSA MARKET SIZE, BY AGE GROUP, 2018-2024 (USD MILLION)
  • TABLE 332. UNITED STATES ANOREXIA NERVOSA MARKET SIZE, BY AGE GROUP, 2025-2032 (USD MILLION)
  • TABLE 333. CANADA ANOREXIA NERVOSA MARKET SIZE, BY TREATMENT TYPE, 2018-2024 (USD MILLION)
  • TABLE 334. CANADA ANOREXIA NERVOSA MARKET SIZE, BY TREATMENT TYPE, 2025-2032 (USD MILLION)
  • TABLE 335. CANADA ANOREXIA NERVOSA MARKET SIZE, BY THERAPY TYPE, 2018-2024 (USD MILLION)
  • TABLE 336. CANADA ANOREXIA NERVOSA MARKET SIZE, BY THERAPY TYPE, 2025-2032 (USD MILLION)
  • TABLE 337. CANADA ANOREXIA NERVOSA MARKET SIZE, BY PHARMACOTHERAPY, 2018-2024 (USD MILLION)
  • TABLE 338. CANADA ANOREXIA NERVOSA MARKET SIZE, BY PHARMACOTHERAPY, 2025-2032 (USD MILLION)
  • TABLE 339. CANADA ANOREXIA NERVOSA MARKET SIZE, BY PSYCHOTHERAPY, 2018-2024 (USD MILLION)
  • TABLE 340. CANADA ANOREXIA NERVOSA MARKET SIZE, BY PSYCHOTHERAPY, 2025-2032 (USD MILLION)
  • TABLE 341. CANADA ANOREXIA NERVOSA MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 342. CANADA ANOREXIA NERVOSA MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 343. CANADA ANOREXIA NERVOSA MARKET SIZE, BY AGE GROUP, 2018-2024 (USD MILLION)
  • TABLE 344. CANADA ANOREXIA NERVOSA MARKET SIZE, BY AGE GROUP, 2025-2032 (USD MILLION)

TAB

Have a question?
Picture

Jeroen Van Heghe

Manager - EMEA

+32-2-535-7543

Picture

Christine Sirois

Manager - Americas

+1-860-674-8796

Questions? Please give us a call or visit the contact form.
Hi, how can we help?
Contact us!